REVB director granted 15,625 shares at $1.28; owns 15,686

Revelation Biosciences (REVB) reported an insider equity award.

Rhea-AI Filing Summary

Revelation Biosciences (REVB) reported an insider equity award. Director Jess Roper acquired 15,625 shares of Common Stock on 10/29/2025 at $1.28 per share, coded as an acquisition. Following the transaction, the director beneficially owned 15,686 shares, held directly.

The shares were a Restricted Stock Grant under the 2021 Equity Incentive Plan and vest 100% on January 28, 2026.

Insider Trade Summary

Grant/Award: 15,625 shares

Grant/Award 2 txns

Insider ROPER JESS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,625	$1.28	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 15,747 shares (Direct)

Footnotes (1)

1. F1. Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did REVB disclose in this Form 4?

A director, Jess Roper, acquired 15,625 shares of Common Stock as a restricted stock grant.

What was the transaction date and price for REVB’s Form 4?

The transaction occurred on 10/29/2025 at $1.28 per share.

How many REVB shares does the insider own after this transaction?

Beneficial ownership following the transaction is 15,686 shares, held directly.

What is the nature of the REVB shares reported?

They are a Restricted Stock Grant under the 2021 Equity Incentive Plan.

When do the restricted REVB shares vest?

The award vests 100% on January 28, 2026.

What is the insider’s relationship to REVB?

The reporting person is a Director of Revelation Biosciences, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 12:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROPER JESS

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								61	D
Common Stock(1)	10/29/2025		A		15,625	A	$1.28	15,686	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026

	/s/ J.P. Galda, as attorney-in-fact for Jess Roper	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.